Skip to main content
All lobbying filings

AKEBIA THERAPEUTICS, INC.

Lobbying for AKEBIA THERAPEUTICS, INC.

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · Massachusetts · House · Senate · $480,000.00 expenses · posted Apr 20, 2026

Official filing document

 Bills named in this filing 4
  • HR 2199
    Restore Protections for Dialysis Patients Act
  • S 1173
    Restore Protections for Dialysis Patients Act
  • HR 6214
    Kidney Care Access Protection Act
  • S 2730
    Kidney Care Access Protection Act
 Lobbying activity 2
Health Issues

H.R. 2199/S. 1173, Restore Protections for Dialysis Patients Act H.R. 6214, Kidney Care Access Protection Act S. 2730, Kidney Care Access Protection Act Implementation of P.L. 118-14, Continuing Appropriations Act, 2024 and Other Extensions Act, including provisions related to Title III, Health and Human Services. Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance. FY 2026 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Implementation of P.L. 118-158, the American Relief Act of 2025, including provisions relating to health care.

Medicare/Medicaid

Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions. Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program. Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease. CMSs inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS). Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients. Final CY 2026 End Stage Renal Disease (ESRD) Prospective Payment System (PPS), Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury (AKI), End Stage Renal Disease Quality Improvement Program (QIP), and End Stage Renal Disease Treatment Choices Model (ETC).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem